Please use this identifier to cite or link to this item: http://hdl.handle.net/11690/2197
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStefani, Luciana Paula Cadore-
dc.contributor.authorLeite, Fabrício Maia-
dc.contributor.authorTarragó, Maria da Graça Lopes-
dc.contributor.authorZanette, Simone de Azevedo-
dc.contributor.authorSouza, Andressa de-
dc.contributor.authorCastro, Stela Maris de Jezus-
dc.contributor.authorCaumo, Wolnei-
dc.date.accessioned2021-09-14T21:33:18Z-
dc.date.available2021-09-14T21:33:18Z-
dc.date.issued2019-
dc.identifier.citationSTEFANI, L. C. et al. BDNF and serum S100B levels according the spectrum of structural pathology in chronic pain patients. Neuroscience Letters, v. 706, p. 105-109, 2019. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0304394019303398?via%3Dihub. Acesso em: 14 set. 2021.pt_BR
dc.identifier.urihttp://hdl.handle.net/11690/2197-
dc.description.abstractCentral sensitivity syndrome (CSS) consists of adaptive pathophysiological changes associated with neuroplasticity in some chronic pain disorders. It could be grouped in two main conceptual conditions: one includes those chronic pain patients without overt structural pathology such as fibromyalgia, and the other subgroup includes conditions with recognizable structural abnormalities, both somatic (osteoarthritis) and visceral (endometriosis). In order to understand the role of neuromodulators in CCS we aim to determine whether brain-derived neurotrophic factor (BDNF) and S100B are associated to specific chronic pain disorders. Serum BDNF and S100B were measured in chronic pain women with different diagnosis: 88 with osteoarthritis, 36 with endometriosis, 117 with fibromyalgia, 33 with chronic tension type headache and in 41 healthy controls. ANCOVA analysis followed by heteroscedasticity-consistent covariance matrix was performed to evaluate BDNF and S100B levels, adjusted for depression severity, pain levels and use of analgesics according different pathologies. Serum BDNF concentrations were higher and not different in patients with fibromyalgia and headache, the CSS group without structural pathology. In contrast, the concentrations of S100B were higher in patients with osteoarthritis and endometriosis, in comparison to controls, fibromyalgia and tensional headache patients. This study supports the hypothesis that BDNF and S100B neuromodulators present different serum levels according to the background disease associated to the chronic pain. These have the potential to be studied as markers of active disease or treatment evolution.pt_BR
dc.language.isoen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsOpen Accessen_US
dc.subjectBrain-derived neurotrophic factorpt_BR
dc.subjectCentral sensitization syndromept_BR
dc.subjectFibromyalgiapt_BR
dc.subjectOsteoarthritispt_BR
dc.subjectS100Bpt_BR
dc.subjectTension headachept_BR
dc.titleBDNF and serum S100B levels according the spectrum of structural pathology in chronic pain patientspt_BR
dc.typeArtigopt_BR
Appears in Collections:Artigo de Periódico (PPGSDH)

Files in This Item:
File Description SizeFormat 
lcstefani.etal.pdfOpen Access240,59 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.